Biogen: Observational study closed enrollment, 74 enrolled (Muscular Atrophy, Spinal)
Biogen: Observational study closed enrollment, 74 enrolled (Muscular Atrophy, Spinal). Its enrollment of 74 is below the median of 80 (47th percentile). Dated 10 days ago, it is in the active follow-up window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 74 · 47th percentile of 8,879 ClinicalTrialStartPulse records · 0.9x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Biogen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care |
| NCT ID | NCT04317794 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Muscular Atrophy, Spinal |
| Intervention types | drug |
| Target enrollment | 74 |
| Site countries | South Korea |
| Posted | 2020-03-23 |
| Planned start | 2019-07-02 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-26 |
| enrollment percentile | 47th of 8,879 (median 80, 0.9x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Biogen
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Biogen + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Biogen and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Biogen's enrollment: 47th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
What is the ClinicalTrialStartPulse record for Biogen?
Biogen's Observational study (NCT04317794) in Muscular Atrophy, Spinal, first posted 2020-03-23: enrollment closed (active, not recruiting) (2026-10-26), in an update posted 2026-10-26.
How does Biogen compare to other ClinicalTrialStartPulse records?
Its enrollment of 74 is below the median (47th percentile); smaller records often move faster and face less competition. It is fresh: dated 10 days ago, inside the window where early outreach matters most. Its Score of 75/100 puts it among the stronger signals in this feed.
Biogen vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Biogen | NONUS | 74 | 47th | 2026-10-26 |
| Janssen-Cilag International NV | NONUS | 135 | 68th | 2026-11-03 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | NONUS | 366 | 85th | 2026-11-03 |
| Teva Branded Pharmaceutical Products R&D LLC | NONUS | 1,085 | 95th | 2026-11-03 |
Related records
- Calyxo, Inc.
- Hoffmann-La Roche
- Restor3D
- Kardium Inc.
- Janssen Biotech, Inc.
- Janssen Scientific Affairs, LLC
- Ethicon Endo-Surgery
- Janssen Pharmaceutica N.V., Belgium
- Janssen-Cilag International NV
- Janssen Biotech, Inc.
- Teva Branded Pharmaceutical Products R&D LLC
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only
How to monitor Biogen and peer observational records
Get new ClinicalTrialStartPulse records like Biogen by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.